Tobira Therapeutics Inc. (NASDAQ:TBRA) has earned a consensus rating of “Buy” from the six analysts that are presently covering the company. One analyst has rated the stock with a hold rating and five have issued a buy rating on the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $68.63.
A number of research firms recently issued reports on TBRA. Mizuho reissued a “buy” rating and set a $305.00 target price on shares of Tobira Therapeutics in a research note on Thursday. Cantor Fitzgerald cut Tobira Therapeutics from a “buy” rating to a “hold” rating and increased their target price for the stock from $19.00 to $42.00 in a research note on Wednesday. HC Wainwright reaffirmed a “buy” rating on shares of Tobira Therapeutics in a research report on Tuesday, June 28th. Zacks Investment Research raised Tobira Therapeutics from a “hold” rating to a “buy” rating and set a $13.00 price target for the company in a research report on Wednesday, July 13th. Finally, Cowen and Company reaffirmed a “buy” rating and set a $11.00 price target on shares of Tobira Therapeutics in a research report on Wednesday, August 10th.
Shares of Tobira Therapeutics (NASDAQ:TBRA) traded down 0.89% during trading on Friday, reaching $39.15. 373,547 shares of the company were exchanged. The stock’s market capitalization is $736.84 million. The company has a 50 day moving average price of $7.62 and a 200-day moving average price of $8.70. Tobira Therapeutics has a one year low of $3.76 and a one year high of $41.39.
Tobira Therapeutics (NASDAQ:TBRA) last posted its earnings results on Tuesday, August 9th. The biopharmaceutical company reported ($0.71) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.63) by $0.08. The company earned $1.06 million during the quarter. Equities analysts predict that Tobira Therapeutics will post ($2.65) EPS for the current year.
In other news, major shareholder A/S Novo sold 66,814 shares of the stock in a transaction that occurred on Thursday, June 30th. The stock was sold at an average price of $13.04, for a total value of $871,254.56. Following the completion of the sale, the insider now owns 2,073,022 shares of the company’s stock, valued at approximately $27,032,206.88. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, major shareholder Pentwater Capital Management L acquired 1,624,200 shares of the business’s stock in a transaction dated Thursday, September 22nd. The stock was bought at an average cost of $39.04 per share, with a total value of $63,408,768.00. The disclosure for this purchase can be found here. 6.20% of the stock is owned by insiders.
Several large investors have recently added to or reduced their stakes in TBRA. Schwab Charles Investment Management Inc. bought a new stake in Tobira Therapeutics during the second quarter valued at approximately $177,000. BB Biotech AG bought a new stake in Tobira Therapeutics during the second quarter valued at approximately $5,878,000. State Street Corp increased its stake in Tobira Therapeutics by 155.5% in the second quarter. State Street Corp now owns 109,527 shares of the biopharmaceutical company’s stock valued at $1,377,000 after buying an additional 66,652 shares during the last quarter. Teachers Advisors Inc. increased its stake in Tobira Therapeutics by 287.1% in the second quarter. Teachers Advisors Inc. now owns 14,484 shares of the biopharmaceutical company’s stock valued at $182,000 after buying an additional 10,742 shares during the last quarter. Finally, TFS Capital LLC bought a new stake in Tobira Therapeutics during the second quarter valued at approximately $533,000. 62.02% of the stock is owned by institutional investors.
Tobira Therapeutics Company Profile
Tobira Therapeutics, Inc, formerly Regado Biosciences, Inc, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies to treat liver disease, inflammation, fibrosis and human immunodeficiency virus (HIV). The Company’s lead product candidate, cenicriviroc (CVC), is an immunomodulator and dual inhibitor of C-C Chemokine Receptor 2 (CCR2) and C-C Chemokine Receptor 5 (CCR5) being evaluated for the treatment of non-alcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC), and as an adjunctive therapy to standard of care in HIV.
Receive News & Ratings for Tobira Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tobira Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.